CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
dc.contributor.author | Walls, G. M. | |
dc.contributor.author | Oughton, J. B. | |
dc.contributor.author | Chalmers, A. J. | |
dc.contributor.author | Brown, S. | |
dc.contributor.author | Collinson, F. | |
dc.contributor.author | Forster, M. D. | |
dc.contributor.author | Franks, K. N. | |
dc.contributor.author | Gilbert, A. | |
dc.contributor.author | Hanna, G. G. | |
dc.contributor.author | Hannaway, N. | |
dc.contributor.author | Harrow, S. | |
dc.contributor.author | Haswell, T. | |
dc.contributor.author | Hiley, C. T. | |
dc.contributor.author | Hinsley, S. | |
dc.contributor.author | Krebs, Matthew G | |
dc.contributor.author | Murden, G. | |
dc.contributor.author | Phillip, R. | |
dc.contributor.author | Ryan, A. J. | |
dc.contributor.author | Salem, Ahmed | |
dc.contributor.author | Sebag-Montefoire, D. | |
dc.contributor.author | Shaw, P. | |
dc.contributor.author | Twelves, C. J. | |
dc.contributor.author | Walker, K. | |
dc.contributor.author | Young, R. J. | |
dc.contributor.author | Faivre-Finn, C. | |
dc.contributor.author | Greystoke, A. | |
dc.date.accessioned | 2020-11-16T07:49:18Z | |
dc.date.available | 2020-11-16T07:49:18Z | |
dc.date.issued | 2020 | en |
dc.identifier.citation | Walls GM, Oughton JB, Chalmers AJ, Brown S, Collinson F, Forster MD, et al. CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clin Transl Radiat Oncol. 2020;25:61-6. | en |
dc.identifier.pmid | 33072895 | en |
dc.identifier.doi | 10.1016/j.ctro.2020.09.006 | en |
dc.identifier.uri | http://hdl.handle.net/10541/623448 | |
dc.description.abstract | Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1016/j.ctro.2020.09.006 | en |
dc.title | CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer | en |
dc.type | Article | en |
dc.contributor.department | Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland, UK. | en |
dc.identifier.journal | Clinical and Translational Radiation Oncology | en |
dc.description.note | en] | |
refterms.dateFOA | 2020-11-17T09:20:10Z |